CA-TIGO
8.5.2024 15:01:37 CEST | Business Wire | Press release
Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy software solutions, today announced the newest additions to the Tigo Flex MLPE product family, the Tigo TS4-X line. Designed to serve the commercial and industrial (C&I) as well as utility solar markets, Tigo TS4-X products support the latest high-power solar modules, up to 800W. Members of the TS4-X product family feature compatibility with Pure Signal™ technology in Tigo RSS Transmitters and offer a Multi-Factor Rapid Shutdown (MFRS) option with redundant safety signaling for solar systems serving the food and pharmaceutical cold-chain sectors, or other energy-critical applications. The new devices pair with an industry-leading list of third-party solar inverters to deliver design and installation flexibility for solar installers and engineering, procurement, and construction specialists (EPCs).
As Levelized Cost Of Energy (LCOE) continues to drive the large-scale solar sectors, the TS4-X product line gives installers more freedom to deploy the modules that deliver the power and performance for their customer deployments and reduces labor costs with a no-bolt design and no need for additional ground wiring. The new products are the TS4-X-O with optimization and advanced module-level monitoring, the TS4-X-S with advanced monitoring, and the rapid shutdown-only TS4-X-F, all of which feature:
- 25A Isc rating and 80V maximum input voltage with plug-and-play support for all solar modules up to 800W,
- new MFRS capability via wired PLC as well as wireless connections for redundant first responder safety and performance assurance in energy-critical applications,
- the option for selective optimizer deployment,
- the first-in-its-class capability for field-upgradable monitoring without the need for MLPE hardware replacement, and
- over-current and over-temperature protection for MLPE devices.
Tigo TS4-X MLPE devices are IEC and UL certified for global acceptance and are compliant with NEC 2017 and 2020 690.12 Rapid Shutdown specifications when installed with the Tigo RSS Transmitter and UL PVRSS-certified inverter or an inverter with a built-in Tigo-certified transmitter. With reliable frame mounting requiring only 10 seconds for installation, TS4-X devices include industry-standard MC4 connectors with an IP68 enclosure rating for maximum durability.
“The installers operating at the cutting edge of solar are pushing the envelope on system output as well as cost, and the TS4-X closes an important gap at the top end of the module performance spectrum,” said Jing Tian, chief growth officer at Tigo Energy. “As the solar industry evolves, Tigo Energy remains at the forefront of providing solutions that empower installers and developers. With safety, versatility, and compatibility at its core, the TS4-X is an advancement in MLPE technology, aligning with Tigo's commitment to innovative software, total quality solar, and customer satisfaction.”
Tigo TS4-X devices work seamlessly with previous TS4 Flex MLPE devices, Tigo Cloud Connect Advanced (CCA) data logging devices, and Tigo RSS Transmitters, and are UL PVRSS certified with hundreds of inverter models from leading manufacturers to deliver safety, versatility, and compatibility. To learn more about the TS4-X product line, visit: https://www.tigoenergy.com/ts4-x. TS4-X products are available for purchase today - contact the Tigo sales team for additional details: https://www.tigoenergy.com/contacts
About Tigo Energy
Founded in 2007, Tigo is a worldwide leader in the development and manufacture of smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Tigo combines its Flex MLPE (Module Level Power Electronics) and solar optimizer technology with intelligent, cloud-based software capabilities for advanced energy monitoring and control. Tigo MLPE products maximize performance, enable real-time energy monitoring, and provide code-required rapid shutdown at the module level. The company also develops and manufactures products such as inverters and battery storage systems for the residential solar-plus-storage market. For more information, please visit www.tigoenergy.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508108008/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom